Vertex Pharmaceuticals Inc
F:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
F:VX1
Watchlist
Price: 392.3 EUR 1.06% Market Closed
Market Cap: 101.3B EUR

Intrinsic Value

The intrinsic value of one VX1 stock under the Base Case scenario is 284.14 EUR. Compared to the current market price of 392.3 EUR, Vertex Pharmaceuticals Inc is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VX1 Intrinsic Value
284.14 EUR
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Vertex Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about VX1?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is VX1 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Vertex Pharmaceuticals Inc.

Explain Valuation
Compare VX1 to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Vertex remains heavily dependent on its cystic fibrosis portfolio, and any slowdown in CF sales or an unexpected competitor breakthrough could significantly impact its top line.

Attempts to diversify into areas such as pain management and gene editing have yet to generate commercialized treatments, raising concerns about the long-term sustainability of its pipeline beyond CF.

High R&D spending and the premium pricing structure of its CF therapies may attract increased scrutiny from regulators and payers, potentially hurting margins.

Bull Theses

Vertex’s CF franchise holds a dominant market position, with new therapies continually maintaining or expanding its share in this high-value therapeutic area.

Successful partnerships and investments in gene editing programs, including the CRISPR collaboration, offer promising new revenue streams and diversify its pipeline beyond cystic fibrosis.

The company’s robust balance sheet, combined with strong free cash flow from CF product sales, provides ample resources to fuel further R&D and strategic acquisitions.

Show More Less
How do you feel about VRTX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vertex Pharmaceuticals Inc

Current Assets 10.6B
Cash & Short-Term Investments 6.3B
Receivables 1.9B
Other Current Assets 2.3B
Non-Current Assets 14.3B
Long-Term Investments 5.7B
PP&E 3B
Intangibles 1.5B
Other Non-Current Assets 4B
Current Liabilities 4.5B
Accounts Payable 4B
Other Current Liabilities 441.5m
Non-Current Liabilities 3.1B
Other Non-Current Liabilities 3.1B
Efficiency

Free Cash Flow Analysis
Vertex Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Vertex Pharmaceuticals Inc

Revenue
11.7B USD
Cost of Revenue
-1.6B USD
Gross Profit
10.1B USD
Operating Expenses
-5.6B USD
Operating Income
4.5B USD
Other Expenses
-861.3m USD
Net Income
3.7B USD
Fundamental Scores

VX1 Profitability Score
Profitability Due Diligence

Vertex Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Exceptional Operating Margin
Exceptional Gross Margin
Exceptional ROIC
Positive 3Y Average ROIC
60/100
Profitability
Score

Vertex Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

VX1 Solvency Score
Solvency Due Diligence

Vertex Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
87/100
Solvency
Score

Vertex Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VX1 Price Targets Summary
Vertex Pharmaceuticals Inc

Wall Street analysts forecast VX1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VX1 is 430.69 EUR with a low forecast of 286.5 EUR and a high forecast of 545.16 EUR.

Lowest
Price Target
286.5 EUR
27% Downside
Average
Price Target
430.69 EUR
10% Upside
Highest
Price Target
545.16 EUR
39% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Vertex Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VRTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

VRTX Insider Trading
Buy and sell transactions by insiders

VX1 News

Other Videos
What is the Intrinsic Value of one VX1 stock?

The intrinsic value of one VX1 stock under the Base Case scenario is 284.14 EUR.

Is VX1 stock undervalued or overvalued?

Compared to the current market price of 392.3 EUR, Vertex Pharmaceuticals Inc is Overvalued by 28%.

Back to Top